Modality
Nanobody
MOA
Anti-Tau
Target
PRMT5
Pathway
Apoptosis
ObesityADHD
Development Pipeline
Preclinical
~Apr 2014
→ ~Jul 2015
Phase 1
~Oct 2015
→ ~Jan 2017
Phase 2
~Apr 2017
→ ~Jul 2018
Phase 3
~Oct 2018
→ ~Jan 2020
NDA/BLA
~Apr 2020
→ ~Jul 2021
Approved
Oct 2021
→ Apr 2028
ApprovedCurrent
NCT07326952
1,354 pts·ADHD
2021-10→2028-04·Terminated
NCT04500037
2,660 pts·ADHD
2025-05→2027-05·Terminated
4,014 total pts1 indication
CompletedCurrentUpcoming
Catalysts (2)
2027-05-201.1y awayPh3 Readout· ADHD
2028-04-132.0y awayPh3 Readout· ADHD
Trial Timeline
Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2
Approved
Termina…
Approved
Termina…
Catalysts
Ph3 Readout
2027-05-20 · 1.1y away
ADHD
Ph3 Readout
2028-04-13 · 2.0y away
ADHD
Terminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07326952 | Approved | ADHD | Terminated | 1354 | DOR |
| NCT04500037 | Approved | ADHD | Terminated | 2660 | Biomarker |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Nirarelsin | Johnson & Johnson | Phase 2 | PRMT5 | |
| RHH-7558 | Roche | Phase 1 | SGLT2 | |
| NVS-5439 | Novartis | Preclinical | BET | |
| MRK-853 | Merck & Co | Phase 1 | PRMT5 | |
| Geliderotide | Sanofi | Phase 1/2 | PRMT5 | |
| Capifutibatinib | Sanofi | Approved | PRMT5 | |
| NVO-9630 | Novo Nordisk | Phase 2 | CD3 | |
| NVO-9615 | Novo Nordisk | Phase 2/3 | PRMT5 | |
| Suracagene | GSK | Phase 3 | PRMT5 | |
| REG-2172 | Regeneron | Phase 1/2 | PCSK9 |